Medicare and Medicaid
Our work in Medicare and Medicaid
-
The Future of Medicare’s Coverage with Evidence Development Policy
Join the USC Schaeffer Center in partnership with the Tufts Center for Evaluation of Value and Risk in Health and the Stanford Byers Center for Biodesign, for a conversation on the future of CED.
Categorized in -
Comments to Representatives DeGette and Bucshon on Building on the Successes of 21st Century Cures
Schaeffer Center experts provided comments to lawmakers on additional measures for enhancing or improving the effectiveness of the 21st Century Cures Act.
Categorized in -
Growing Divergence Between Medicare Advantage Plan Bids and Payments to Plans
While risk-adjusted Medicare Advantage bids have decreased compared with risk-adjusted traditional Medicare spending, total payments to MA plans have risen partly because of the growing impact of payment adjustments.
Categorized in -
Study: Exploding Popularity of Ozempic and Wegovy Among Privately Insured Patients May Worsen Disparities
Publicly insured individuals who are most likely to benefit from new diabetes and obesity drugs are less likely to get them than those with private insurance.
Categorized in -
Comments to CMS on Transcatheter Tricuspid Valve Replacement (TTVR) and Broader CED Policy Considerations
Schaeffer Center experts provided comments to CMS on issues with how Coverage with Evidence Determination policy is applied.
Categorized in -
Estimating Overpayments to MA Plans: MedPAC Critics Get It Wrong
Why many of the key assertions in a recent Forefront article challenging the MedPAC’s estimate that favorable selection and upcoding increase payments to Medicare Advantage (MA) plans in 2024 by $83 billion are wrong.
Categorized in -
Access to New Alzheimer’s Treatments Bogged Down by Medicare Policy
There are now two Alzheimer’s treatments with significant clinical benefit. It’s not clear how quickly patients will be able to benefit.
Categorized in -
Fixing Medicare Advantage With Competitive Bidding
Schaeffer experts recommend using competitive bidding for standardized benefits to set plan payments and enhance beneficiary choice in Medicare Advantage.
Categorized in -
Analysis: Competitive Bidding Vital to Ensuring Sustainability of Medicare Advantage
Schaeffer Center researchers detail how a competitive bidding structure – whereby plans compete on price and quality – would improve the MA program.
Categorized in -
Shingles Vaccination in Medicare Part D After Inflation Reduction Act Elimination of Cost Sharing
Unlike commercially insured individuals who have no cost sharing for recommended vaccinations, in 2021, Medicare beneficiaries receiving vaccines covered under Medicare Part D paid $234 million out of pocket (OOP), with a mean OOP cost of $76.94 for shingles vaccines.
Categorized in